公开(公告)号：US10463712B2

公开(公告)日：2019-11-05

申请号：US15569045

申请日：2016-04-25

Applicant: University of Manitoba

Inventor： Jean-Eric Ghia ,  Mohammed Fazle Alam Rabbi ,  Ehsan Khafipour ,  Peris Munyaka

IPC: A61K38/04 ,  A61K38/16 ,  A61K38/00 ,  C07K14/00 ,  A61K38/17 ,  C07K14/575

Abstract: Treatment with catestatin changes the proportion of two major phyla Bacteroidetes and Firmicutes in the gut microbiota in an opposite manner observed in intestinal disorders like IBD, IBS or non-intestinal disorders like obesity. Specifically, administration of an effective amount of catestatin increased the relative percentage of Bacteroidetes and decreased the relative percentage of Firmicutes in the gut microbiota.

公开(公告)号：US20180125927A1

公开(公告)日：2018-05-10

申请号：US15569045

申请日：2016-04-25

Applicant: University of Manitoba

Inventor： Jean-Eric Ghia ,  Mohammed Fazle Alam Rabbi ,  Ehsan Khafipour ,  Peris Munyaka

IPC: A61K38/17

CPC classification number: A61K38/1709 ,  C07K14/575

Abstract: Treatment with catestatin changes the proportion of two major phyla Bacteroidetes and Firmicutes in the gut microbiota in an opposite manner observed in intestinal disorders like IBD, IBS or non-intestinal disorders like obesity. Specifically, administration of an effective amount of catestatin increased the relative percentage of Bacteroidetes and decreased the relative percentage of Firmicutes in the gut microbiota.